Previous close | 42.51 |
Open | 42.48 |
Bid | 42.26 x 2900 |
Ask | 42.70 x 800 |
Day's range | 42.34 - 42.62 |
52-week range | 27.37 - 45.76 |
Volume | |
Avg. volume | 44,250 |
Market cap | 1.598B |
Beta (5Y monthly) | 0.61 |
PE ratio (TTM) | 34.80 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 10 Dec 2018 |
1y target est | N/A |
The Indian drugmaker, which currently owns about 78.5% stake in Taro, had offered to buy its remaining stake for $38 per share in May. Upon completion of the merger, which is expected to close in the first half of the year, Taro would become a privately held company and will be delisted from the New York Stock Exchange, the companies said. The U.S. government had in November dismissed charges against a former Taro executive who was accused of conspiring to fix generic drug prices between 2013 and 2015.
Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential. However, overdependence on Galafold for revenues remains a concern.
Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.